XML 30 R18.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Stockholders’ Equity | 9 Months Ended
--- | ---
Jun. 30, 2024
Stockholders’ Equity [Abstract] |
Stockholders’ Equity | NOTE 11 – Stockholders’ Equity At-The-Market Offering On December 21, 2022, the Company entered into a Capital on DemandTM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC (“JonesTrading”) that created an at-the-market offering program (“ATM”) under which the Company may offer and sell common stock having an aggregate offering price of up to $14.5 million. JonesTrading is entitled to a commission at a fixed commission rate of up to 3% of the gross proceeds. On July 24, 2023, the Company decreased the amount of common stock that can be sold pursuant to the Sales Agreement, such that the Company was offering up to an aggregate of $2.6 million of its common stock for sale under the Sales Agreement, including the shares of common stock previously sold. Subsequently on December 1, 2023, however, the Company increased the amount of common stock that can be sold pursuant to the Sales Agreement, such that the Company was offering up to an aggregate of $4.8 million of its common stock for sale under the Sales Agreement, including the shares of common stock previously sold. On January 5, 2024, the Company further increased the amount of common stock that can be sold pursuant to the Sales Agreement, such that the Company is offering up to an aggregate of $9.3 million of its common stock for sale under the Sales Agreement, including the shares of common stock previously sold. During the three and nine months ended June 30, 2024, 1,419,317 and 3,748,913 shares of common stock were issued, respectively, under the ATM for an aggregate offering price of $1,683,439 and $5,033,906, respectively. Issuance costs incurred under the ATM during the three and nine months ended June 30, 2024 were $50,519 and $236,599, respectively. During the three and nine months ended June 30, 2023, 923,193 and 1,439,677 shares of common stock were issued, respectively, under the ATM for an aggregate offering price of $1,624,399 and $2,552,656 during these periods, respectively. Issuance costs incurred during the three and nine months ended June 30, 2023 was $51,366 and 234,725, respectively. The total aggregate offering price and common stock issued since inception of the ATM though June 30, 2024 was $7,586,562 and 5,188,590 shares, respectively. Cumulative issuance costs incurred under the ATM through June 30, 2024 were $471,323. Warrant Activity and Summary There were no warrant exercises and 1,338,860 warrants expired during the nine months ended June 30, 2024, respectively. The following table summarizes information about warrants outstanding at June 30, 2024:
|  | Warrants |  |  | Exercise Price Per Warrant |  |  | Weighted Average Exercise Price |  |  | Weighted Average Term (Years) |
Outstanding and exercisable at September 30, 2023 |  |  | 6,202,426 |  |  | $ | 3.00-9.00 |  |  | $ | 5.92 |  |  |  | 2.00 |
Issued |  |  | — |  |  | $ | — |  |  | $ | — |  |  |  | — |
Exercised |  |  | — |  |  | $ | — |  |  | $ | — |  |  |  | — |
Expired |  |  | (1,338,860 | ) |  | $ | 7.50-9.00 |  |  | $ | 8.69 |  |  |  | — |
Outstanding and exercisable at June 30, 2024 |  |  | 4,863,566 |  |  | $ | 3.00-9.00 |  |  | $ | 5.16 |  |  |  | 1.73 |
The following table summarizes information about warrants outstanding at June 30, 2024:
Exercise Price |  |  | Number Outstanding |  |  | Weighted Average Remaining Contractual life (Years) |  |  | Number Exercisable
$ | 3.00 |  |  |  | 350,000 |  |  |  | 3.09 |  |  | 350,000
$ | 5.25 |  |  |  | 4,166,682 |  |  |  | 1.54 |  |  | 4,166,682
$ | 5.61 |  |  |  | 220,855 |  |  |  | 4.00 |  |  | 220,855
$ | 6.00 |  |  |  | 45,171 |  |  |  | 0.00* |  |  | 45,171
$ | 8.25 |  |  |  | 62,906 |  |  |  | 0.00* |  |  | 62,906
$ | 9.00 |  |  |  | 17,952 |  |  |  | 0.00* |  |  | 17,952
Total |  |  |  | 4,863,566 |  |  |  |  |  |  | 4,863,566
* | Under 0.001

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration